Hyloris Developmentsen Sa (HYL) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Hyloris Developmentsen Sa stock €3.03, price €4.25, that is 28.7% below the price, quality 47 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Hyloris Developmentsen Sa
HYL · BRExpensive (fair value 29% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range €3.30 – €18.90 · fair‑value band €2.27 – €3.78 · the €4.25 price screens above the €3.03 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Hyloris Developmentsen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific.
Show moreShow less
The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections.
It also provides Atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder; XTRAZA and Tranexamic Acid IV RTU for the prevention and treatment of excessive bleeding; HY-094 Iron IV to treat iron deficiency; and Pantoprazole IV for short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis.
In addition, the company is involved in the development of Alenura for painful bladder syndrome; Phosphate oral liquid for phosphate supplementation; and HY-095 PPI for the treatment of gastric ulcers in horses.
Further, it develops Aspirin IV for acute coronary syndrome indication; Milrinone for late-stage HF with LVAD; Dofetilide IV for atrial fibrillation indication; HY-074 for acute coronary syndrome indication; Metolazone IV for congestive heart failure indication; and HY-75 for coronary heart disease indication.
The company has collaboration agreements with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
Stock analysis
Hyloris Developmentsen Sa (HYL) currently trades at €4.25, while our estimate is €3.03, 29% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: €2.27 (bear) to €3.78 (bull), the price of €4.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hyloris Developmentsen Sa reported revenue of €7.2M in FY2025 versus €3.1M in FY2021, a compound +23.5%/yr. Reported net income was −€6.3M in FY2025.
Key figures
Market cap €119M Micro · P/S ratio 11.0 · EPS (TTM) €−0.1600 · Net margin −47.4% · Return on equity −17.3% · Return on assets (EBIT) −21.1% (5-year average) · Operating margin −27.1% · Revenue (TTM) €9.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −29%, HYL screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Hyloris Developmentsen Sa with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- PEG screener for stocks with fair value
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs HYL |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs HYL |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs HYL |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs HYL |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs HYL |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs HYL |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs HYL |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs HYL |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs HYL |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs HYL |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Hyloris Developmentsen Sa (HYL) overvalued or undervalued?
What is the fair value of HYL?
What is the quality score of HYL?
What is the price target for Hyloris Developmentsen Sa (HYL)?
What is the Hyloris Developmentsen Sa stock forecast for 2026?
What is the revenue of Hyloris Developmentsen Sa (HYL)?
What is the intrinsic value of Hyloris Developmentsen Sa (HYL)?
Is Hyloris Developmentsen Sa stock overvalued or undervalued in 2026?
Is fair value the same as the market price of HYL?
How much is Hyloris Developmentsen Sa worth?
What do the bullish and bearish scenarios say about HYL?
How solid is the balance sheet of Hyloris Developmentsen Sa (HYL)?
How far is HYL from its 52-week high?
Which stocks are comparable to Hyloris Developmentsen Sa?
Is Hyloris Developmentsen Sa stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Hyloris Developmentsen Sa (HYL)?
What should I pay attention to with Hyloris Developmentsen Sa right now?
Key figures of Hyloris Developmentsen Sa
How large is the market capitalisation of Hyloris Developmentsen Sa (HYL)?
What is the P/S ratio of Hyloris Developmentsen Sa (HYL)?
What are the earnings per share of Hyloris Developmentsen Sa (HYL)?
What is the net margin of Hyloris Developmentsen Sa (HYL)?
What is the return on equity of Hyloris Developmentsen Sa (HYL)?
What is the EBIT return on assets of Hyloris Developmentsen Sa (HYL)?
What is the operating margin of Hyloris Developmentsen Sa (HYL)?
How fast is revenue growing at Hyloris Developmentsen Sa (HYL)?
How much free cash flow does Hyloris Developmentsen Sa (HYL) generate?
How much net cash does Hyloris Developmentsen Sa (HYL) hold?
Watch Hyloris Developmentsen Sa in the live analysis
One click puts Hyloris Developmentsen Sa on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.